 Objectives The principal objective is to assess the accuracy of the newly developed Point-of-Care genotyping assay Genedrive IL-28B Assay to detect in HCV patients the genotype CC versus non CC i.e. CT and TT against the TaqMan Allelic Discrimination Assay as gold standard. 